Huo Meng-Yue, Mei Hua, Zhang Yu-Heng, Liu Chun-Zhi, Hu Ya-Nan, Song Dan
Department of Neonatology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2020 Jul;22(7):721-727. doi: 10.7499/j.issn.1008-8830.2001043.
To evaluate the efficacy and safety of less invasive surfactant administration (LISA) in the treatment of neonatal respiratory distress syndrome (NRDS).
PubMed, Cochrane Library, Embase, China Biology Medicine disc, China Scientific Journal Database, CNKI Database, and Wanfang Database were searched for randomized controlled trials (RCTs) on the use of LISA strategy in the treatment of NRDS. Literature screening and quality assessment were performed according to inclusion and exclusion criteria. Review Manager 5.3 software was used to perform the Meta analysis.
A total of 9 RCTs were included, with a total of 1 212 children with NRDS. There were 611 children in the experimental group (treated with LISA strategy) and 601 children in the control group [treated with intubation-surfactant-extubation (INSURE) strategy]. The Meta analysis showed that the use of LISA strategy reduced the rate of mechanical ventilation within 72 hours after birth (OR=0.39, 95%CI: 0.29-0.51, P<0.001) and the incidence rates of bronchopulmonary dysplasia (OR=0.53, 95%CI: 0.38-0.72, P<0.001) and pneumothorax (OR=0.56, 95%CI: 0.33-0.93, P=0.02). There were no significant differences in the mortality rate and incidence rates of other neonatal diseases between the two groups (P>0.05). There was no significant difference in the rate of repeated use of pulmonary surfactant (PS) between the two groups (P>0.05), but there was a higher incidence rate of PS reflux observed by LISA strategy (OR=2.60, 95%CI: 1.64-4.12, P<0.001).
Compared with INSURE strategy, LISA strategy has advantages in reducing the need for mechanical ventilation and the incidence rates of bronchopulmonary dysplasia and pneumothorax in children with NRDS.
评估微创表面活性剂给药(LISA)治疗新生儿呼吸窘迫综合征(NRDS)的疗效和安全性。
检索PubMed、Cochrane图书馆、Embase、中国生物医学光盘数据库、中国科学期刊数据库、CNKI数据库和万方数据库,查找关于使用LISA策略治疗NRDS的随机对照试验(RCT)。根据纳入和排除标准进行文献筛选和质量评估。使用Review Manager 5.3软件进行Meta分析。
共纳入9项RCT,涉及1212例NRDS患儿。实验组(采用LISA策略治疗)611例,对照组[采用插管-表面活性剂-拔管(INSURE)策略治疗]601例。Meta分析显示,使用LISA策略可降低出生后72小时内机械通气率(OR=0.39,95%CI:0.29-0.51,P<0.001)、支气管肺发育不良发生率(OR=0.53,95%CI:0.38-0.72,P<0.001)和气胸发生率(OR=0.56,95%CI:0.33-0.93,P=0.02)。两组间死亡率及其他新生儿疾病发生率差异无统计学意义(P>0.05)。两组间肺表面活性物质(PS)重复使用率差异无统计学意义(P>0.05),但LISA策略观察到的PS反流发生率较高(OR=2.60,95%CI:1.64-4.12,P<0.001)。
与INSURE策略相比,LISA策略在降低NRDS患儿机械通气需求、支气管肺发育不良和气胸发生率方面具有优势。